Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 15/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | CASP9 | P55211 | 1/20 | 0.52 |
| ▸ | CASP6 | P55212 | 1/20 | 0.52 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.52 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.52 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22904534 | 0.78 | PARP1 (0.54) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL22526396 | 0.78 | PARP1 (0.54) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL18010801 | 0.78 | CDK5 (0.58) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL261277 | 0.77 | AHR (0.48) | SRD5A1MEN1KMT2AGSK3B | |
| SCHEMBL29622013 | 0.77 | AHR (0.48) | SRD5A1MEN1KMT2AGSK3B | |
| SCHEMBL25123374 | 0.75 | GSK3B (0.50) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL24029524 | 0.75 | TDP2 (0.49) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL30459657 | 0.74 | CDK5 (0.41) | SRD5A1PGR | |
| SCHEMBL29634952 | 0.74 | SRD5A1 (0.42) | SRD5A1KMT2APGR | |
| SCHEMBL22525285 | 0.74 | TDP2 (0.47) | TDP2CASP3CASP7CASP9CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021011631-A1 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |